CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection

This study tests a personalized CAR-T cell therapy — where immune cells taken from your own body are genetically engineered to fight liver cancer — in patients who have had surgery for liver cancer and show signs that the cancer may be coming back. **You may be eligible if...** - You are aged 18–75 with liver cancer that was surgically removed - Your tumor tested positive for a protein called GPC3 - After surgery, your AFP blood marker (a cancer indicator) has been rising, suggesting the cancer may return - Your cancer had blood vessel involvement but no spread outside the liver - Your liver and general health are in reasonably good condition **You may NOT be eligible if...** - Your cancer has already come back or spread - It has been more than 2 years since your surgery - You have HIV, active hepatitis B or C, or active infections - You have had a prior organ transplant or received CAR-T therapy before - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.